...
首页> 外文期刊>International journal of clinical practice >Regression of post-transplant Kaposi's sarcoma using sirolimus.
【24h】

Regression of post-transplant Kaposi's sarcoma using sirolimus.

机译:西罗莫司对卡波西氏肉瘤移植后的消退。

获取原文
获取原文并翻译 | 示例
           

摘要

Kaposi's sarcoma (KS) is a recognised complication following kidney transplantation, but the incidence varies according to the geographical area. Although it is a rare tumour, its incidence increases dramatically after solid-organ transplantation. The immunosuppressive medications reactivate human herpes virus 8, which has been proposed as the offending agent. The usual treatment of KS is to reduce immunosuppression, chemotherapy and radiotherapy. Nevertheless, the mortality still remains considerably high and has been reported between 8 and 14%. Sirolimus (SRL) has properties which may be useful in the management of some posttransplant tumours such as KS. We report a renal transplant patient with KS, who had multiple relapses after radiotherapy but responded well to the change of immunosuppression from cyclosporine to SRL.
机译:卡波济肉瘤(KS)是肾脏移植后公认的并发症,但其发病率因地理区域而异。尽管它是一种罕见的肿瘤,但在实体器官移植后其发病率急剧上升。免疫抑制药物可重新激活人疱疹病毒8,有人提出将其作为违规药物。 KS的常规治疗是减少免疫抑制,化学疗法和放射疗法。尽管如此,死亡率仍然很高,据报道在8%至14%之间。西罗莫司(SRL)具有可用于治疗某些移植后肿瘤(例如KS)的特性。我们报道了一位肾移植患者,KS,放疗后多次复发,但对免疫抑制从环孢素到SRL的变化反应良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号